STOCK TITAN
  1. Home
  2. News
  3. VRCA

Verrica Pharmaceuticals Inc - VRCA STOCK NEWS

Welcome to our dedicated news page for Verrica Pharmaceuticals (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Verrica Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Verrica Pharmaceuticals's position in the market.

News
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Verrica Pharmaceuticals Inc. announces Ted White, President & CEO, will present at the 23rd Annual Needham Virtual Healthcare Conference on April 9, 2024. Investors can register for the live webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
none
-
News
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
Rhea-AI Summary
Verrica Pharmaceuticals Inc. announced that their lead product, YCANTH™, has received New Chemical Entity (NCE) Status and a listing in the Orange Book from the FDA, providing a minimum of five years of regulatory exclusivity. The Company's patents related to YCANTH™ are projected to expire between 2034 and 2041, with potential protection from generic competition for over a decade.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.14%
Tags
none
-
News
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
Rhea-AI Summary
Verrica Pharmaceuticals Inc. reports YCANTH™ revenue of $1.9M for Q4 and $4.7M for full year 2023. Over 200 million lives now covered by commercial insurance and managed Medicaid plans. The company continues to make progress with the launch of YCANTH™, securing a permanent J-Code for billing, and advancing pipeline with successful FDA meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.87%
Tags
earnings
News
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
Rhea-AI Summary
Verrica Pharmaceuticals Inc. will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference in Boston, Massachusetts on March 5, 2024. Investors can access a live webcast of the event on the Verrica website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
none
-
News
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
Rhea-AI Summary
Verrica Pharmaceuticals Inc. will host a conference call to discuss financial results for Q4 and full-year 2023, focusing on dermatology therapeutics. Participants can join via telephone or webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
earnings
-
News
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
Rhea-AI Summary
Verrica Pharmaceuticals Inc. has filed a lawsuit against Dormer Laboratories Inc. for false and misleading advertising of unapproved cantharidin-containing drugs in the US. Verrica seeks to enjoin Dormer Labs from marketing and selling these drugs and is also seeking compensatory, statutory, and punitive damages for violations of federal and Pennsylvania law. The lawsuit is in response to Dormer Labs' promotion of unapproved cantharidin-containing drugs to healthcare providers and customers, despite YCANTH being the only FDA-approved cantharidin-containing drug for molluscum contagiosum.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.58%
Tags
none
News
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services
Rhea-AI Summary
Verrica Pharmaceuticals Inc. announced the issuance of a permanent J-Code for YCANTH™ by the Centers for Medicare & Medicaid Services (CMS), the only FDA-approved treatment for molluscum contagiosum. The J-Code will be fully published on April 1, 2024, expected to accelerate YCANTH utilization among U.S. Medicaid and Medicare patient populations. The permanent J-Code will streamline the billing and reimbursement process for YCANTH, reducing the risk of billing errors and allowing companies to receive pass-through payments through government-sponsored healthcare plans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
none
-
News
Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
Rhea-AI Summary
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announces completion of dosing for Part 2 of Phase 2 trial of VP-315 for the treatment of basal cell carcinoma. The company reiterates lesion clearance data expected in Q2 2024. Basal cell carcinoma affects 3-4 million people in the U.S. annually, with a high unmet need for new treatment options. VP-315 is a potential first-in-class oncolytic peptide designed to stimulate the immune system and destroy cancer cells, offering an alternative to surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
clinical trial
-
News
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts
Rhea-AI Summary
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) received positive feedback from the FDA in a recent Type C meeting regarding the Phase 3 clinical development plan for YCANTH, a medication for common warts. The meeting led to mutual alignment with the FDA on the design of the Phase 3 study, indicating significant potential for YCANTH to address a sizable market opportunity. The company remains focused on addressing unmet needs in dermatology and is evaluating label expansion opportunities for YCANTH.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
clinical trial
News
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™
Rhea-AI Summary
Verrica Pharmaceuticals Inc. (VRCA) announced a distribution agreement with Walgreens to distribute YCANTH™, the first FDA-approved therapy for molluscum contagiosum, to millions of adults and children. The company aims to address the significant unmet medical need in dermatology by expanding its distribution network and working closely with Nufactor, its existing specialty pharmacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
partnership
Stock VRCA logo
Verrica Pharmaceuticals Inc

Nasdaq:VRCA

VRCA Rankings

#3449 Ranked by Market Cap
#576 Ranked by Stock Gains
N/A Ranked by Dividends

VRCA Stock Data

291.42M
15.07M
39.7%
42.59%
9.87%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
West Chester

About VRCA

verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.